Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18778172 | GLUN2B-SUBUNIT SELECTIVE ANTAGONISTS OF THE N-METHYL-D-ASPARTATE RECEPTORS WITH ENHANCED POTENCY AT ACIDIC PH | July 2024 | September 2024 | Allow | 2 | 0 | 0 | No | No |
| 18634865 | 1-(NAPHTHALEN-2-YLOXY)-3-(PIPERIDIN-1-YL)PROPAN-2-OL AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | April 2024 | September 2024 | Allow | 5 | 1 | 0 | No | No |
| 18427164 | RAD51 INHIBITORS | January 2024 | May 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18425961 | 2-(5-(3-FLUOROPHENYL)-4-PHENYL-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AS AN ANTIMICROBIAL COMPOUND | January 2024 | August 2024 | Allow | 7 | 1 | 0 | No | No |
| 18425970 | 2-(5-(3-FLUOROPHENYL)-4-PHENYL-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AS AN ANTIMICROBIAL COMPOUND | January 2024 | August 2024 | Allow | 7 | 2 | 0 | No | No |
| 18417867 | N'-(2-NAPHTHOYLOXY)-2-(BENZO[D]OXAZOL-2-YL)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | January 2024 | September 2024 | Allow | 8 | 0 | 0 | No | No |
| 18405058 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | January 2024 | January 2025 | Allow | 13 | 1 | 1 | No | No |
| 18393818 | METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOF | December 2023 | October 2024 | Abandon | 10 | 1 | 0 | No | No |
| 18388765 | Benzimidazoles and Methods of Using Same | November 2023 | November 2024 | Allow | 12 | 1 | 0 | No | No |
| 18504672 | DEUTERATED COMPOUNDS AND USES THEREOF | November 2023 | November 2024 | Allow | 12 | 1 | 1 | No | No |
| 18491021 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | October 2023 | November 2024 | Allow | 13 | 1 | 0 | No | No |
| 18482475 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | October 2023 | January 2025 | Abandon | 16 | 0 | 1 | No | No |
| 18477050 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | September 2023 | January 2025 | Allow | 16 | 1 | 0 | No | No |
| 18373702 | COMPOUNDS AND USES THEREOF | September 2023 | November 2024 | Allow | 14 | 1 | 0 | No | No |
| 18476249 | FUSED PYRROLINES WHICH ACT AS UBIQUITIN-SPECIFIC PROTEASE 30 (USP30) INHIBITORS | September 2023 | December 2024 | Abandon | 14 | 0 | 1 | No | No |
| 18372417 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | September 2023 | March 2024 | Allow | 5 | 1 | 1 | No | No |
| 18464646 | PHARMACEUTICAL FORMULATIONS COMPRISING A PYRIDYLAMINOACETIC ACID COMPOUND | September 2023 | January 2025 | Allow | 16 | 2 | 0 | No | No |
| 18463707 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FGFR3-RELATED CHONDRODYSPLASIAS | September 2023 | November 2024 | Allow | 14 | 1 | 0 | No | No |
| 18463878 | PHOSPHINE REAGENTS FOR AZINE FLUOROALKYLATION | September 2023 | February 2025 | Abandon | 17 | 1 | 1 | No | No |
| 18448277 | THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF | August 2023 | November 2024 | Allow | 16 | 1 | 0 | No | No |
| 18361558 | HYDROPHILIC ANTIBODY-DRUG CONJUGATES | July 2023 | November 2024 | Allow | 16 | 0 | 1 | No | No |
| 18221353 | FORMULATION OF METAXALONE | July 2023 | December 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18350152 | THIOUREYLENE LIQUID COMPOSITIONS | July 2023 | August 2024 | Allow | 13 | 1 | 0 | No | No |
| 18348114 | METHODS OF INHIBITING KINASES | July 2023 | October 2024 | Allow | 15 | 1 | 0 | No | No |
| 18344169 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | June 2023 | August 2024 | Allow | 14 | 1 | 0 | No | No |
| 18341950 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | June 2023 | October 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18337299 | TREATMENT OF CATAPLEXY | June 2023 | August 2024 | Allow | 13 | 1 | 0 | No | No |
| 18210306 | EIF4E INHIBITORS AND USES THEREOF | June 2023 | February 2024 | Allow | 8 | 0 | 0 | No | No |
| 18132677 | METHOD FOR PRODUCING PYRROLE COMPOUND | April 2023 | September 2024 | Allow | 18 | 0 | 1 | No | No |
| 18114584 | CURCUMIN ANALOGUES AS ZINC CHELATORS AND TEHIR USES | February 2023 | October 2024 | Abandon | 20 | 1 | 1 | No | No |
| 18108053 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | February 2023 | June 2024 | Allow | 17 | 0 | 1 | No | No |
| 18097640 | SUBSTITUTED IMIDAZOLE SALT COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | January 2023 | February 2025 | Allow | 25 | 1 | 1 | No | No |
| 18066677 | METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOF | December 2022 | October 2024 | Abandon | 22 | 0 | 1 | No | No |
| 18057742 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | November 2022 | November 2024 | Allow | 24 | 2 | 1 | No | No |
| 17989859 | CRYSTALLINE EPINEPHRINE MALONATE SALT | November 2022 | June 2024 | Allow | 19 | 1 | 0 | No | No |
| 17905973 | PYRIMIDOHETEROCYCLIC COMPOUNDS AND APPLICATION THEREOF | September 2022 | July 2024 | Allow | 22 | 0 | 1 | No | No |
| 17940585 | INSECT REPELLENT COMPOUNDS AND COMPOSITIONS, AND METHODS THEREOF | September 2022 | October 2024 | Abandon | 26 | 2 | 1 | No | No |
| 17929931 | PROCESSES FOR PREPARING PLASMA KALLIKREIN INHIBITORS | September 2022 | October 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17929285 | PHARMACEUTICAL COMPOSITIONS COMPRISING ONE OR MORE PYRONE COMPOUNDS, AND THEIR USE FOR TREATING INFLAMMATORY AND NEURODEGENERATIVE DISEASES | September 2022 | September 2024 | Allow | 25 | 2 | 1 | No | No |
| 17788534 | CHEMICAL COMPOUNDS TARGETING THE EYE AND USE THEREOF IN THE TREATMENT OF EYE DISEASES | June 2022 | September 2024 | Allow | 27 | 0 | 0 | No | No |
| 17730112 | INDAZOLE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | April 2022 | February 2024 | Allow | 22 | 2 | 0 | No | Yes |
| 17639302 | METHODS OF SYNTHESIZING CANNABIELSOIN AND ANALOGS THEREOF | February 2022 | July 2024 | Allow | 28 | 0 | 0 | No | No |
| 17632909 | AGONISTS OF ROR GAMMAt | February 2022 | October 2024 | Abandon | 32 | 2 | 1 | No | No |
| 17633151 | CYCLOBUTYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS | February 2022 | October 2024 | Allow | 33 | 1 | 1 | No | No |
| 17627214 | COMPOUNDS AS NLRP3 INFLAMMASOME INHIBITORS AND COMPOSITIONS AND USES THEREOF | January 2022 | November 2023 | Abandon | 22 | 2 | 1 | No | No |
| 17618878 | Compounds For Modulating FXR | December 2021 | May 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17596353 | IMPROVED METHODS FOR CONVERTING CANNABIDIOL INTO DELTA9-TETRAHYDROCANNABINOL UNDER PROTIC REACTION CONDITIONS | December 2021 | May 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17457733 | FUSED THIOPHENE COMPOUNDS | December 2021 | June 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17613910 | METHYL- AND TRIFLUOROMETHYL-CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR | November 2021 | January 2025 | Allow | 38 | 1 | 0 | No | No |
| 17608434 | COMPOUNDS AND METHODS FOR TREATING CANCER | November 2021 | January 2025 | Allow | 39 | 1 | 1 | No | No |
| 17605170 | MELOXICAM CO-CRYSTAL COMPOSITIONS | October 2021 | May 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17469773 | SELF-ASSEMBLED ACTIVE AGENTS | September 2021 | April 2024 | Allow | 31 | 3 | 1 | No | No |
| 17446807 | PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY | September 2021 | May 2023 | Allow | 20 | 1 | 0 | No | No |
| 17310941 | PREPARATION OF MAYTANSINOL | September 2021 | October 2024 | Allow | 37 | 0 | 1 | No | No |
| 17370201 | COMPOUNDS FOR TREATMENT OF CANCER | July 2021 | June 2024 | Allow | 35 | 3 | 1 | No | No |
| 17359661 | SYNTHESIS METHOD FOR HALOFUGINONE AND HALOFUGINONE INTERMEDIATES | June 2021 | January 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17351350 | BUTHIONINE SULFOXIMINE AND A METALLODRUG FOR THE TREATMENT OF CANCER, HIV OR A RHEUMATIC DISEASE | June 2021 | July 2024 | Allow | 37 | 3 | 1 | No | No |
| 17283441 | AZAINDOLE INHIBITORS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | April 2021 | December 2024 | Allow | 44 | 1 | 1 | No | No |
| 17272346 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | February 2021 | July 2024 | Allow | 40 | 3 | 1 | No | No |
| 17161275 | STRAD-binding agents and Uses Thereof | January 2021 | August 2024 | Allow | 43 | 4 | 1 | No | No |
| 17055550 | FATTY ACID ANALOGUES AND METHODS OF USE | November 2020 | November 2024 | Allow | 48 | 5 | 1 | No | No |
| 17095876 | COMPOUNDS AND FORMS OF TREATMENT FOR FEMALE SEXUAL DISORDERS | November 2020 | December 2024 | Abandon | 49 | 0 | 1 | No | No |
| 17044079 | Polycyclic Carbamoylpyridone Derivatives, Pharmaceutical Compositions and Use Thereof | September 2020 | August 2024 | Allow | 46 | 1 | 1 | No | No |
| 17041703 | Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy | September 2020 | December 2024 | Allow | 51 | 1 | 1 | No | No |
| 16487832 | SUBSTITUTED [5,6]CYCLIC-4(3H)-PYRIMIDINONES AS ANTICANCER AGENTS | August 2019 | June 2020 | Allow | 10 | 0 | 0 | No | No |
| 16331088 | NEW CRYSTALLINE FORM OF SACUBITRIL SODIUM SALT | March 2019 | March 2020 | Allow | 12 | 0 | 1 | No | No |
| 16223224 | COMPOUNDS AND THEIR USE IN TREATING CANCER | December 2018 | June 2019 | Allow | 6 | 0 | 0 | No | No |
| 16309845 | SULFONIC ACID ESTER COMPOUND AND USE THEREFOR | December 2018 | August 2019 | Allow | 9 | 0 | 0 | No | No |
| 16190285 | NOVEL 5-SUBSTITUTED IMIDAZOLE DERIVATIVES | November 2018 | September 2019 | Allow | 10 | 0 | 1 | No | No |
| 16096098 | SUBSTITUTED 2-ALKYLIMIDAZOLYLCARBOXAMIDES AS PESTICIDES | October 2018 | March 2020 | Allow | 17 | 2 | 1 | No | No |
| 16037447 | SILANOL BASED THERAPEUTIC PAYLOADS | July 2018 | February 2020 | Allow | 19 | 0 | 1 | No | No |
| 15991705 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | May 2018 | November 2019 | Allow | 18 | 2 | 0 | No | No |
| 15969222 | AMIDE-SUBSTITUTED PYRIDINYLTRIAZOLE DERIVATIVES AND USES THEREOF | May 2018 | July 2019 | Allow | 14 | 1 | 0 | No | No |
| 15915989 | CHEMICAL ENTITIES THAT KILL SENESCENT CELLS FOR USE IN TREATING AGE-RELATED DISEASE | March 2018 | August 2019 | Allow | 17 | 0 | 1 | No | No |
| 15914958 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | March 2018 | June 2019 | Allow | 15 | 3 | 1 | No | No |
| 15736242 | Halogen-substituted phenoxyphenylamidines and the use thereof as fungicides | December 2017 | November 2018 | Allow | 11 | 1 | 0 | No | No |
| 15827074 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | November 2017 | January 2018 | Allow | 2 | 0 | 0 | No | No |
| 15817760 | TRIPLE REUPTAKE INHIBITORS AND METHODS OF THEIR USE | November 2017 | May 2019 | Allow | 18 | 2 | 0 | No | No |
| 15567668 | AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS | October 2017 | November 2018 | Allow | 13 | 0 | 1 | No | No |
| 15725363 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF | October 2017 | August 2018 | Allow | 10 | 1 | 0 | No | No |
| 15726263 | ENAMINONE-GRAFTED TRITHIOCARBONATE WITH ANTICANCER AND ANTIMICROBIAL ACTIVIITY | October 2017 | May 2018 | Allow | 7 | 1 | 0 | Yes | No |
| 15563414 | Novel 5-substituted imidazole derivatives | September 2017 | November 2018 | Allow | 14 | 2 | 1 | No | No |
| 15560265 | HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR | September 2017 | May 2019 | Allow | 20 | 3 | 0 | No | No |
| 15631380 | TRIFLUOROMETHYL PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | June 2017 | May 2018 | Allow | 11 | 1 | 0 | No | No |
| 15538959 | Polymorphic Forms of Methyl((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl) carbonyl)-2-methylpropyl)carbamate and Salts Thereof | June 2017 | February 2019 | Allow | 20 | 1 | 1 | No | No |
| 15614371 | TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | June 2017 | January 2019 | Allow | 19 | 2 | 1 | No | No |
| 15609813 | Oxaspiro[2.5]Octane Derivatives and Analogs | May 2017 | December 2018 | Allow | 18 | 0 | 0 | No | No |
| 15531638 | PESTICIDALLY ACTIVE AMIDE HETEROCYCLIC DERIVATIVES WITH SULPHUR CONTAINING SUBSTITUENTS | May 2017 | August 2019 | Allow | 26 | 2 | 1 | No | No |
| 15527687 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | May 2017 | January 2020 | Allow | 32 | 2 | 0 | No | No |
| 15523518 | FOLATE-CONJUGATED MOLECULES FOR DELIVERY OF TOXIC SMALL MOLECULE INHIBITORS TO CANCER CELLS AND METHODS OF USE | May 2017 | August 2019 | Allow | 27 | 1 | 1 | No | No |
| 15522191 | POLYHETEROARL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | April 2017 | August 2019 | Allow | 28 | 2 | 1 | No | No |
| 15479086 | THERAPEUTIC ISOXAZOLE COMPOUNDS | April 2017 | April 2018 | Allow | 12 | 1 | 0 | No | No |
| 15506045 | TETRAHYDRO-AZEPINOQUINOLINES AS AGONISTS OF THE 5-HT2C RECEPTOR | February 2017 | June 2018 | Allow | 16 | 0 | 0 | No | No |
| 15439733 | LOW DOSE PHARMACEUTICAL COMPOSITION | February 2017 | July 2019 | Allow | 29 | 3 | 0 | No | No |
| 15421729 | PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | February 2017 | November 2017 | Allow | 10 | 1 | 0 | No | No |
| 15417860 | ANTICANCER DRUGS INCLUDING THE CHEMICAL STRUCTURES OF AN ANDROGEN RECEPTOR LIGAND AND A HISTONE DEACETYLASE INHIBITOR | January 2017 | January 2018 | Allow | 11 | 1 | 0 | No | No |
| 15328366 | CHARGE-TRANSPORTING MATERIAL | January 2017 | July 2018 | Allow | 18 | 0 | 1 | No | No |
| 15320813 | THIOPHEN-2-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | December 2016 | May 2017 | Allow | 5 | 0 | 0 | No | No |
| 15355108 | METHOD FOR PREPARING N,N'-BIS(2-CYANOETHYL)-1,2-ETHYLENEDIAMINE BY USING CATION EXCHANGE RESIN AS CATALYST | November 2016 | August 2017 | Allow | 9 | 0 | 0 | No | No |
| 15355103 | METHOD FOR PREPARING N,N'-BIS(2-CYANOETHYL)-1,2-ETHYLENEDIAMINE | November 2016 | August 2017 | Allow | 9 | 0 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SHTERENGARTS, SAMANTHA L.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 28.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SHTERENGARTS, SAMANTHA L works in Art Unit 1623 and has examined 605 patent applications in our dataset. With an allowance rate of 96.7%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 22 months.
Examiner SHTERENGARTS, SAMANTHA L's allowance rate of 96.7% places them in the 90% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by SHTERENGARTS, SAMANTHA L receive 1.11 office actions before reaching final disposition. This places the examiner in the 16% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by SHTERENGARTS, SAMANTHA L is 22 months. This places the examiner in the 79% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +3.5% benefit to allowance rate for applications examined by SHTERENGARTS, SAMANTHA L. This interview benefit is in the 24% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 41.2% of applications are subsequently allowed. This success rate is in the 91% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 72.9% of cases where such amendments are filed. This entry rate is in the 92% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 87.5% of appeals filed. This is in the 78% percentile among all examiners. Of these withdrawals, 85.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 56.0% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 19.2% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.